Clinical Trials Directory

Trials / Conditions / Grade 2 Follicular Lymphoma

Grade 2 Follicular Lymphoma

19 registered clinical trials studyying Grade 2 Follicular Lymphoma — 4 currently recruiting.

StatusTrialSponsorPhase
RecruitingPirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROM
NCT06948786
University of WashingtonPhase 2
RecruitingLow Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma
NCT06442475
University of WashingtonPhase 2
RecruitingCombination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphom
NCT06471738
Chinese PLA General HospitalPhase 2
CompletedMosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-C
NCT05169658
University of WashingtonPhase 2
RecruitingAcalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent
NCT04883437
Emory UniversityPhase 2
Active Not RecruitingObinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymph
NCT04450173
University of California, DavisPhase 2
Active Not RecruitingAcalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma
NCT04257578
University of WashingtonPhase 1 / Phase 2
CompletedTLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade
NCT03410901
Ronald LevyPhase 1
Active Not RecruitingObinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas
NCT03198026
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityPhase 2
Active Not RecruitingObinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With R
NCT03269669
National Cancer Institute (NCI)Phase 2
CompletedEntospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocy
NCT03010358
Alexey Danilov, MDPhase 1 / Phase 2
Active Not RecruitingObinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin
NCT02992522
Beth ChristianPhase 1
CompletedPembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
NCT02950220
Kami MaddocksPhase 1
CompletedTLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1
NCT02927964
Robert LowskyPhase 1 / Phase 2
CompletedIbrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage
NCT02532257
M.D. Anderson Cancer CenterPhase 2
CompletedSalvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma
NCT02652715
Mayo ClinicN/A
CompletedProlonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia
NCT01484015
Wake Forest University Health SciencesPhase 1
CompletedVaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell
NCT01239875
Mayo ClinicEARLY_Phase 1
CompletedCollecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma
NCT01000753
Children's Oncology Group—